Management of chemotherapy‐induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with colorectal cancer (CC): An interim analysis of an ongoing French national observational study (The OncoBOS study)
| Autor: | Jean Philippe Metges, Jean-Pierre Crumbach, Daniela Petran, Vincent Boulanger, Otilia Stamerra, Jérôme Desramé, Sophie Nahon, Camille Aubron-Olivier, Domitille Fernet, Gilles Boschetti |
|---|---|
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 33:742-742 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2015.33.3_suppl.742 |
| Popis: | 742 Background: OncoBOS is a prospective, non-interventional study describing Binocrit use in routine practice in France in patients receiving chemotherapy treatment (CT) for solid tumors, lymphoma, or myeloma. This interim sub-analysis focuses on patients with CC, receiving usual chemotherapeutic agents. Methods: Patients ≥18 years with CC, CIA, and eligible for treatment with Binocrit were included in this analysis. Patients characteristics, data on CIA and its management, and predominant factors considered by the physician in prescribing Binocrit were recorded at baseline (BL), 3-4 weeks and 12 (±1) weeks later. Hemoglobin (Hb) outcomes assessed included the proportion of patients achieving a Hb increase ≥1 and ≥2 g/dL, and the mean Hb change from BL. Results: 96 patients with CC (51 males [53.1%], mean age 68.5 years) from 28 sites were recruited from September 2011 to April 2014. Mean and median BL Hb levels were 9.9 g/dL and 10 g/dL, respectively. The mean increase in Hb level was 1.2 g/dL after 1 month and 1.7 g/dL after 3 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|